Skip to main content

ADVERTISEMENT

Videos

John Allan, MD, Weill Cornell Medicine
Conference Coverage
04/06/2024

Featuring John Allan, MD

Featuring John Allan, MD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, John Allan, MD, shares expert insight on the impact targeted agents have in the treatment of CLL, focusing particularly on frontline therapy.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, John Allan, MD, shares expert insight on the impact targeted agents have in the treatment of CLL, focusing particularly on frontline therapy.
At the 2024 Great Debates &...
04/06/2024
Oncology
Samuel Yamshon, MD
Conference Coverage
04/06/2024

Featuring Samuel Yamshon, MD

Featuring Samuel Yamshon, MD
During the Great Debates & Updates in Hematologic Malignancies meeting, Samuel Yamshon, MD, examines the efficacy of using CAR T-cell therapy to treat elderly patients with relapsed/refractory diffuse large B-cell lymphoma.
During the Great Debates & Updates in Hematologic Malignancies meeting, Samuel Yamshon, MD, examines the efficacy of using CAR T-cell therapy to treat elderly patients with relapsed/refractory diffuse large B-cell lymphoma.
During the Great Debates &...
04/06/2024
Oncology
Peter Martin, MD
Conference Coverage
04/06/2024

Featuring Peter Martin, MD

Featuring Peter Martin, MD
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting in New York, Peter Martin, MD, argued in favor of alternative treatment regimens over CAR T-cell therapy for treating follicular lymphoma.
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting in New York, Peter Martin, MD, argued in favor of alternative treatment regimens over CAR T-cell therapy for treating follicular lymphoma.
During the 2024 Great Debates &...
04/06/2024
Oncology
Jordan Axelrad
Conference Coverage
04/06/2024
Dr Axelrad discusses his presentation at the AIBD regional meeting on the value and positioning of sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease.
Dr Axelrad discusses his presentation at the AIBD regional meeting on the value and positioning of sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease.
Dr Axelrad discusses his...
04/06/2024
Advances in Inflammatory Bowel Disease Network
Robert Stillman, MA, RN
Videos
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
04/06/2024

Featuring John Allan, MD

Featuring John Allan, MD
At the 2024 Great Debates & Updates Meeting in Hematological Malignancies in New York, John Allan, MD, discusses if there is a role for chemo-immunotherapy in the CLL treatment landscape.
At the 2024 Great Debates & Updates Meeting in Hematological Malignancies in New York, John Allan, MD, discusses if there is a role for chemo-immunotherapy in the CLL treatment landscape.
At the 2024 Great Debates &...
04/06/2024
Lymphoma, Leukemia & Myeloma Network
Anna Halpern, MD
Videos
04/06/2024

Featuring Anna Halpern, MD

Featuring Anna Halpern, MD
Anna Halpern, MD, discusses her National Comprehensive Cancer Network annual conference session on how to balance inpatient and outpatient oncology care.
Anna Halpern, MD, discusses her National Comprehensive Cancer Network annual conference session on how to balance inpatient and outpatient oncology care.
Anna Halpern, MD, discusses her...
04/06/2024
Journal of Clinical Pathways
Joshua Richter, MD
Conference Coverage
04/05/2024

Featuring Joshua Richter, MD

Featuring Joshua Richter, MD
Joshua Richter, MD, discusses promising novel advances in the multiple myeloma treatment landscape, including the use of T-cell redirection therapy and possible treatment approvals to come.
Joshua Richter, MD, discusses promising novel advances in the multiple myeloma treatment landscape, including the use of T-cell redirection therapy and possible treatment approvals to come.
Joshua Richter, MD, discusses...
04/05/2024
Lymphoma, Leukemia & Myeloma Network
Joshua Richter, MD
Conference Coverage
04/05/2024

Featuring Joshua Richter, MD

Featuring Joshua Richter, MD
At the 2024 Great Debates & Updates in Hematologic Malignancies, Joshua Richter, MD, explores the role of minimal residual disease in multiple myeloma treatment strategies, addressing whether it should be used to make clinical decisions for...
At the 2024 Great Debates & Updates in Hematologic Malignancies, Joshua Richter, MD, explores the role of minimal residual disease in multiple myeloma treatment strategies, addressing whether it should be used to make clinical decisions for...
At the 2024 Great Debates &...
04/05/2024
Lymphoma, Leukemia & Myeloma Network
Tejaswi Kompala
Videos
04/05/2024

Featuring Tejaswi Kompala, MD, head of cardiometabolic clinical strategy, Teladoc 

Featuring Tejaswi Kompala, MD, head o...
Delve into the rising demand for anti-obesity medications, the complexities of obesity management, and the importance of personalized approaches in improving cardiometabolic health in this insightful interview.
Delve into the rising demand for anti-obesity medications, the complexities of obesity management, and the importance of personalized approaches in improving cardiometabolic health in this insightful interview.
Delve into the rising demand for...
04/05/2024
First Report Managed Care